Case-Based Roundtable Meeting Spotlight November 1 2021 | Case-Based Roundtable Meetings Spotlight

Experts Discuss Diagnostic and Treatment Options for a Patient With mCRPC

November 10, 2021

Clinical Articles

After 8 months on enzalutamide, a 75-year-old patients with metastatic castration-resistant prostate cancer showed a PSA level of 60.7 ng/mL, enlargement of known pelvic lymph nodes, and progressive disease.